Agreement with Advanced Accelerator Applications
EVEON signed an agreement with the pharmaceutical group Advanced Accelerator Applications for a medical injection device in oncology.
EVEON's objective is to develop and produce an innovative automated injection system for the treatment of solid tumours.
EVEON, designer and manufacturer of medical devices for the preparation and administration of medicinal products, signed, in december 2014, an agreement with Advanced Accelerator Applications (AAA), a European leader in the production and marketing of radiopharmaceutical products for PET (Positron emission tomography).
AAA is a major name in personalised and nuclear medicine. The group is committed to the development of new therapeutic product candidates.
Along with other partners, AAA is currently working on a strategic industrial innovation project called "TheraneaM – Therapy by neutron activation using Microparticles" that aims to develop a technology of innovative micro-curietherapy for the treatment of solid tumours.
As part of this project backed by BPIFrance, AAA is developing a new treatment technique that requires a precise injector. EVEON has taken on the development and delivery of this injector for clinical phases, as well as beyond for marketing phases.
In this context, AAA sought to enlist the skills and expertise of EVEON in order to entrust them with the development and future production of an automated system for the intratumoral administration of radioactive microparticles for the treatment of solid tumours.
"We are proud to have signed this agreement with a European leader in molecular nuclear medicine," explained Vincent Tempelaere, CEO of EVEON. "This agreement reinforces EVEON's position as a major name in oncology. Cancer treatment is experiencing a revolution thanks to new surgical practices, but also thanks to the arrival of new targeted treatments. EVEON plans to play a major role in this transition by providing a simple and precise technology for administering these treatments, for the benefit of healthcare professional and also for that of patients."
For the first 2 indications targeted as part of this project, brain metastases and pancreatic cancer, nearly 100,000 patients would be eligible for this new therapy.
"We are glad to be collaborating with EVEON. Their technology is extremely interesting, and in it, we see real potential for molecular nuclear therapy," added Stefano Buono, CEO of AAA.
- Press contact: Vincent Tempelaere +33 476 414 833
For more information, download the full press release.
